Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan

Longer survival in patients with multiple myeloma (MM) after treatment with novel agents (NA) such as thalidomide, bortezomib, and lenalidomide may be associated with increased risks of developing second primary malignancies (SPM). Few data describe the risk of SPM in patients with MM in Asia. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanfang, Hou, Hsin-An, Qiu, Hong, Tang, Chao-Hsiun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463238/
https://www.ncbi.nlm.nih.gov/pubmed/32873831
http://dx.doi.org/10.1038/s41598-020-71243-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463238/
https://www.ncbi.nlm.nih.gov/pubmed/32873831
http://dx.doi.org/10.1038/s41598-020-71243-z

Ejemplares similares